Back to top
more

PTC Therapeutics (PTCT)

(Delayed Data from NSDQ)

$78.98 USD

78.98
2,870,286

+0.45 (0.57%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $78.92 -0.06 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 6.36% and 11.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PTC Therapeutics Gets First Milestone Payment for SMA Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

Zacks Equity Research

PTC Therapeutics' Application for SMA Drug Accepted by EU

by Zacks Equity Research

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -105.43% and -5.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

by Zacks Equity Research

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

Zacks Equity Research

PTC Therapeutics Initiates Phase II/III Study for Coronavirus

by Zacks Equity Research

PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.

Zacks Equity Research

Pfizer Reports Efficacy & Safety Data on DMD Gene Therapy

by Zacks Equity Research

Pfizer's (PFE) new phase Ib data on its investigational gene therapy, PF-06939926 in ambulatory boys with DMD support advancement to a pivotal phase III study.